Gene Polymorphisms Increasing the Risk of Intracranial Aneurysms: Interleukin-1β -511C>T (Part I)

Alice Giotta Lucifero 1, Matias Baldoncini 2, Thomas Foiadelli  3, Ilaria Brambilla  3, Gabriele Savioli  4, Renato Galzio  5, Alvaro Campero 6,7, Michael T. Lawton 8, Sabino Luzzi 1,9

1 Neurosurgery Unit, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy, 2 Department of Neurological Surgery, Hospital San Fernando, Buenos Aires, Argentina, 3 Pediatric Clinic, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy; 4 Emergency Medicine and Surgery, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy; 5 Neurosurgery Unit, Maria Cecilia Hospital, Cotignola, Italy; 6 Servicio de Neurocirugía, Universidad Nacional de Tucumán; Argentina; 7 Department of Neurosurgery, Hospital Padilla, San Miguel de Tucumán, Argentina; 8 Department of Neurosurgery, Barrow Neurological Institute (BNI), United States; 9 Neurosurgery Unit, Department of Surgical Sciences, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Abstract. Introduction: Intracranial aneurysms (IAs) are devastating cerebrovascular diseases with multifactorial etiology. The role of inflammation is indisputable, and interleukins are pivotal in supporting local inflammatory pathways and endothelial dysfunction at the aneurysm wall. In the light of insufficient evidence reported in the literature, this meta-analysis was aimed to investigate the genetic linkage between IL-1β (rs16944) -511C>T polymorphisms and IAs susceptibility. Methods: A comprehensive online literature review was completed using the PubMed/Medline and Web of Science databases in accordance with the PRISMA guidelines. “Interleukin-1β,” “IL-1β,” “polymorphism,” “intracranial aneurysm,” and “subarachnoid hemorrhage” were the main keywords. Only human case-control studies, published from 2005 to 2021, written in English or translated, were screened. In the statistical analysis, we applied the fixed- and random-effect models, according to the level of heterogeneity, to assess the odds ratios (ORs) and 95% confidence intervals (CIs). RevMan 5.0 software was used for the statistics. Results: Only 4 studies were eligible, with a total of 2070 patients, 1050 of which were assigned to the study group. Combined results showed a statistically significant association between the risk of IAs and -511CC (OR=0.79, 95% CI [0.65-0.95], p=0.01), and CT (OR=0.69, 95% CI [0.58-0.82], p<0.0001; OR=0.71, 95% CI [0.55-0.93], p=0.01) allele variations, both in the fixed- and random-effect models. No correlation was identified for the -511TT genotype (p=0.42; p=0.78). All the texts showed a low level of publication bias. Conclusion: The present meta-analysis proved a potential role of IL-1β -511CC/CT genotypes in the pathogenesis of IAs. Additional studies are imperative to explain the underlying neuroimmune mechanisms, also allowing tailoring the potential inflammatory-target therapies for IAs. (www.actabiomedica.it)

Key words: Allele Variations; Gene Polymorphisms; IL-1β; Inflammatory Cytokines; Interleukin-1β; Intracranial Aneurysm; Subarachnoid Hemorrhage.

Introduction

Proinflammatory cytokines, as interleukins (ILs), control the adaptive immune response and upregulate inflammatory reactions. Recent advances in immunogenetics strongly support the liability of ILs in the pathogenesis of neuro-oncological and neurovascular diseases including intracranial aneurysms (IAs) (1-10). IAs are focal vessels enlargements featured by histological changes and vascular remodeling of the arterial wall (11-13). Recruit-
ing of macrophages, T lymphocytes, and platelets, infiltration of proteases and ILs through vessels wall, lead to endothelial dysfunction and arterial weakening (14-17). Thinning of vascular layers increases IAs growth, resulting in rupture and subarachnoid hemorrhage (SAH) (18-22). The interleukin-1β (IL-1β), a pleiotropic cytokine, promotes lymphocytes activation, boosts the immune cascade, and regulates inflammatory pathways (23-25). The genetic cluster, which encodes for the IL-1 family, was mapped on chromosome 2. C>T polymorphisms of the IL-1β gene, at the -511promoter region (rs16944), affect the over-expression of IL-1β and, consequently, promote inflammatory pathways (25-27).

The increased immune response and the high serum concentration of IL-1β may influence the IAs’ natural history, worsening morbidity and mortality of SAH (28, 29).

Our meta-analysis intends to explore the genetic linkage between -511C>T polymorphic variations of IL-1β genotype and IAs susceptibility in different population samples. Future perspectives and novel immunotherapeutic targets are also discussed.

Methods

**Literature selection process**

The PubMed/Medline (https://pubmed.ncbi.nlm.nih.gov) and Web of Science (https://www.webofscience.com) online databases were used for the literature review, which was reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) recommendations. The keywords were “interleukin-1β,” “IL-1β,” “interleukin-1β polymorphism,” “IL-1β polymorphism,” “interleukin-1β genotype,” “IL-1β genotype”, combined with “intracranial aneurysm,” “brain aneurysm,” and “subarachnoid hemorrhage.” The inclusion criteria were set as follows: articles written in English or translated, reference period ranging between 2005 and 2021, case-control human studies, genome-wide linkage analysis for IL-1β -511C>T (rs16944) polymorphisms, availability data on allele frequencies (CC/CT/TT).

Studies involving animals, those lacking a control group, editorials, letters to editors, reviews, and case reports were excluded. Eligible articles were filtered based on the best match and relevance. The quality level of the articles was estimated through the Newcastle-Ottawa quality assessment scale (NOS). A NOS score greater than 6 documented a high-quality study.

**Statistical analysis**

The Mantel-Haenszel method for fixed effects was applied to estimate the pooled odds ratios (ORs) and 95% confidence intervals (CIs). Heterogeneity of the study sample was calculated by Cochrane’s Q test, whereas p <0.05 and I² >50% were considered significant. In the case of high-level heterogeneity, the Der Simonian–Laird method was used for the random effects model. Z-test for overall effect was always completed and the ORs and CIs of each endpoint were built in as Forest plots. The p-value was set at < 0.05. Begg’s rank correlation and Egger’s regression asymmetry methods were used to assess the risks of publication bias. The relative funnel plots were reported. RevMan 5.0 software (Cochrane Informatics & Knowledge Management Department) was used for the meta-analysis.

**Results**

**Literature Volume**

The search retrieved a total of 58 articles. After removing duplicates, screening, and application of the exclusion criteria, 9 studies were found initially eligible. Then implementation of the inclusion criteria allowed to select 4 studies. Figure 1 shows the PRISMA flow chart on the study (Figure 1).

All studies tested allelic frequencies of the IL-1β gene -511C>T (rs16944) polymorphisms. 3 articles were prospective observational and the other retrospective. NOS score was 6 in 2 studies and 7 in the remaining. The studies were conducted in Italy, China, India, and Poland.

**Demographics and Genetic Data**

1050 IAs belonged to the study groups, whereas the control groups consisted of 1020 healthy subjects,
for a total of 2070 recruited patients. The average patients’ age was 55 and 56.8 years for the IAs groups and control groups, respectively. Males were 40.5% and 34.6% in the study and control groups, respectively. Patients’ demographics and genetic records were summarized in Table 1.

Quantitative Synthesis and Heterogeneity Analysis

Cochrane’s Q test revealed a high level of heterogeneity (I²=77%, I²=53%, I²=79%) for all the tests. Accordingly, both fixed- and random-effect model was applied in the entire dataset. Concerning the -511CC polymorphism, the results were as follows: OR=0.79, 95% CI [0.65-0.95], p=0.01, and OR=0.79, 95% CI [0.53-1.18], p=0.25, for the fixed- and random-effect model, respectively (Figure 2).

Both fixed and random model analysis on the -511CT polymorphism unveiled high statistical significance: OR=0.69, 95% CI [0.58-0.82], p<0.0001; and OR=0.71, 95% CI [0.55-0.93], p=0.01 (Figure 3).

Results of the -511TT genotype examination were as follows: OR=0.91, 95% CI [0.72-1.15], p=0.42; OR=1.08, 95% CI [0.62-1.88], p=0.78, for the fixed- and random-effect models, respectively (Figure 4).
Figure 2. Forest plot for -511CC polymorphism

Figure 3. Forest plot for -511CT polymorphism
Publication Bias

Low risks of bias were detected by Begg’s rank and Egger’s methods for the -511CC/CT/TT genotypes evaluation (Figure 5).

Discussion

The present study was aimed to prove the associations between IL-1β -511C>T genotype variations and the risk of IAs.

-511C>T polymorphisms stimulate the aberrant production of IL-1β and the systemic increment of immune and inflammatory processes (25-27). The abnormal expression of IL-1β was demonstrated to interfere with the pathogenesis and prognosis of several neurological disorders, as multiple sclerosis, Parkinson’s and Alzheimer’s disease, and high-grade brain tumors (27, 30-41). The rise of IL-1β in serum concentration and cerebrospinal fluid of SAH-patients explains its role in the genesis and rupture of IAs (42, 43). Furthermore, the local interleukin increase triggers the endothelial dysfunction at the aneurysm wall by upregulating the

Figure 4. Forest plot for -511TT polymorphism

Figure 5. Funnel plot for -511 CC/CT/TT polymorphisms
synthesis of proteases, leukocytes’ adhesion molecules, and nitric oxide (NO) (17).

Data about the potential causative role of IL-1β genotypes in the formation and progression of IAs are contradictory and scant, accounting only for 4 case-control studies. In 2006, Slowik and colleagues reported a case-control study on 231 SAH patients. They genotyped the IL-1β polymorphisms finding a link between the -511TT allele variation and the risk of IAs (44). In 2010, a prospective study involving 215 consecutive patients affected by IAs was performed on the Italian population, whose results did not support any genetic association between IL-1β and aneurysmal SAH (45). Sathyan et al. conducted genetic tests for cytokine genes in the population of south India concerning the IL-1β rs16944 polymorphisms, confirming no genetic liability (46). Even a more recent study by Xu and colleagues, in 2021, failed to identify genetic associations between aneurysms and IL-1β in univariate and multivariate logistic regression analyses (47).

Contrary to what was reported by every single study, our meta-analysis highlighted a strong association between -511C>T polymorphisms and brain aneurysms. Despite the high level of heterogenicity, both fixed- and random-effects models proved significant genetic relationships between the -511CC (p=0.01) and 511CT (p<0.0001; p=0.01) polymorphisms. The present data can be interpreted as a starting point for future researches aimed to identify genetic aspects involved in the natural history of IAs, concurrently providing valuable insights for the management of SAH (19, 48).

Future Perspectives: Anti-Inflammatory Target Therapy

The overactivation of the inflammatory cascade is responsible for the IAs progression and the post-SAH complications also, including cerebral ischemia, cortical spreading depression, hydrocephalus, and vasospasm (28, 49-55).

In-depth knowledge of molecular pathways, underlying the inflammation-based aneurysmal development, is of dramatic importance to identify novel therapeutic targets (56). Blood products, interleukins, chemokines, and tumor necrosis factors bind respective ligands, expressed on endothelial cells, and upregulate leukocytes activation (57-59).

In this rationale, one among the earlier therapeutic approach was aimed at inhibiting the activation of lymphocytes and suppressing the immune response (60).

Since 1998, the ISUIA study (International Study of Unruptured Intracranial Aneurysms) investigated the role of acetylsalicylic acid (ASA) in preventing IAs rupture (61-63). ASA acts as an antiplatelet and anti-inflammatory agent. It blocks cyclooxygenase 2, inhibits the recruitment of macrophages, suppresses the metalloproteinases, and increases endothelium protection by NO (61, 64-68). Despite encouraging premises, the ASA was not finally approved as prophylactic for unruptured IAs. Statins have a pleiotropic effect in reducing the local immune response and increasing NO production (69-71). A combined treatment, ASA plus statins, has been tested on human and animal models and was potentially effective to reduce the risk of aneurysm rupture (72-74).

Lymphocytes’ activity can also be modulated through the T-helper regulatory cells. Boosting the T-reg expression is a potentially valid approach in reducing inflammation and preserving endothelial integrity (75-79). M2 macrophages are involved in the tissue repairing processes and collagen production, counterbalancing the proinflammatory reaction of the microglia. Further advanced strategies were designed to promote the polarization of the microglial M2 and to heighten their neuroprotective effect (80-82).

Stem cell-based approaches have a rationale for IAs similarly to what known in neuro-oncology and regenerative medicine. In fact, mesenchymal stem cells may be theoretically administered to modulate the pro-inflammatory microenvironment and prevent the aneurysm rupture (83-88). Furthermore, emerging therapeutic frontiers are based on the neuro-immune communication strategies through the vagus nerve stimulation or tailoring of NO and acetylcholine receptors, to suppress the inflammatory microenvironment post-SAH (89, 90).

Limitations of the Study

The main limitations of this meta-analysis are the unavoidable selection bias, the limited number of patients involved, and the high population hetero-
geneity. Moreover, the acquired risk factors were not considered.

Conclusion

Genetic polymorphisms of proinflammatory cytokines increase the production of ILs, ultimately resulting in the upregulation of inflammatory processes at the IAs wall.

As opposed to what was reported by previous case-control studies, the present meta-analysis showed a direct association between the IL-1β -511CC/CT allele variations and the occurrence of IAs.

Further ethnicity-related data are necessary to clarify the genetic linkage between IL-1β and SAH, concurrently providing future directions for clinical research and novel therapeutic strategies.

Conflict of Interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.

References

1. Tricarico PM, Epate A, Celsi F, Crovella S. Alendronate treatment induces IL-1β expression and apoptosis in glioblastoma cell line. Inflammopharmacology. 2018;26(1):285-90.

2. Ho KH, Chen PH, Hsi E, Shih CM, Chang WC, Cheng CH, et al. Identification of IGF-1-enhanced cytokine expressions targeted by miR-181d in glioblastomas via an integrative miRNA/mRNA regulatory network analysis. Sci Rep. 2017;7(1):732.

3. Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, et al. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with alfercept. Target Oncol. 2013;8(2):117-25.

4. Palumbo P, Lombardi F, Augello FR, Giusti I, Luzzi S, Dolo V, et al. NOS2 inhibitor 1400W Induces Autophagic Flux and Influences Extracellular Vesicle Profile in Human Glioblastoma U87MG Cell Line. Int J Mol Sci. 2019;20(12).

5. Savioli G, Ceresa IF, Macedonio S, Gerola S, Belliato M, Iotti GA, et al. Trauma Coagulopathy and Its Outcomes. Medicina (Kaunas). 2020;56(4).

6. Foiadelli T, Savasta S, Battiston A, Kota M, Passera C, Fiore S, et al. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis. BMC Infect Dis. 2016;16:277.

7. Gastaldi M, Scaranzini S, Jarius S, Wildeman B, Zarzini E, Mallucci G, et al. Cell-based assays for the detection of MOG antibodies: a comparative study. J Neurol. 2020;267(12):3555-64.

8. Foiadelli T, Gastaldi M, Scaranzini S, Franciotta D, Savasta S. Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: Two paradigmatic cases and a review of the literature. Mult Scler Relat Disord. 2020;41:102011.

9. Giacomini T, Foiadelli T, Annovazzi P, Nosadini M, Gastaldi M, Franciotta D, et al. Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients. Mult Scler Relat Disord. 2019;39:101917.

10. Orsini A, Foiadelli T, Carli N, Costagliola G, Masini B, Bonuccelli A, et al. Rasmussen’s encephalitis: From immune pathogenesis towards targeted-therapy. Seizure. 2020;81:76-83.

11. Juvela S. Prevalence of and risk factors for intracranial aneurysms. Lancet Neurol. 2011;10(7):595-7.

12. Rinkel GJ, Djibuti M, Algra A, van Gijn J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke. 1998;29(1):251-6.

13. Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol. 2011;10(7):626-36.

14. Frösen J, Piippo A, Paetau A, Kangasniemi M, Niemelä M, Hernesniemi J, et al. Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke. 2004;35(10):2287-93.

15. Cebral JR, Dettmer F, Chung BJ, Choque-Velasquez J, Rezaei B, Lehto H, et al. Local Hemodynamic Conditions Associated with Focal Changes in the Intracranial Aneurysm Wall. AJNR Am J Neuroradiol. 2019;40(3):510-6.

16. Tulamo R, Frösen J, Hernesniemi J, Niemelä M. Inflammatory changes in the aneurysm wall: a review. J Neurointerv Surg. 2010;2(2):120-30.

17. Giotta Lucifero A, Baldoni M, Bruno N, Galzio R, Hernesniemi J, Luzzi S. Shedding the Light on the Natural History of Intracranial Aneurysms: An Updated Overview. Medicina (Kaunas). 2021;57(8).

18. Etminan N, Chang HS, Hackenberg K, de Rooij NK, Vergouwen MDI, Rinkel GJE, et al. Worldwide Incidence of Aneurysmal Subarachnoid Hemorrhage According to Region, Time Period, Blood Pressure, and Smoking Prevalence in the Population: A Systematic Review and Meta-analysis. JAMA Neurol. 2019;76(5):588-97.

19. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306-18.

20. Suarez JJ, Tar RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med. 2006;354(4):387-96.

21. Luzzi S, Gragnaniello C, Giotta Lucifero A, Del Maestro M, Galzio R. Microneurosurgical management of giant intracranial aneurysms: Datasets of a twenty-year experience.
Data Brief. 2020;33:106537.
22. Luzzi S, Gragnaniello C, Giotta Lucifero A, Del Maestro M, Galzio R. Surgical Management of Giant Intracranial Aneurysms: Overall Results of a Large Series. World Neurosurg. 2020;144:e119-e37.
23. Kataoka K, Taneda M, Asai T, Kinoshita A, Ito M, Kuroda R. Structural fragility and inflammatory response of ruptured cerebral aneurysms. A comparative study between ruptured and unruptured cerebral aneurysms. Stroke. 1999;30(7):1396-401.
24. Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol Aging. 2001;22(6):903-8.
25. Hall SK, Perregaux DG, Gabel CA, Woodworth T, Durham LK, Huizinga TW, et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum. 2004;50(6):1976-83.
26. Basu A, Krady JK, Levison SW. Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res. 2004;78(2):151-6.
27. Rothwell NJ, Luheushi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000;23(12):618-25.
28. Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10(1):44-58.
29. Shaftel SS, Griffin WS, O’Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation. 2008;5:7.
30. Nishimura M, Mizuta I, Mizuta E, Yamasaki S, Ohta M, Kuno S. Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinson’s disease. Neurosci Lett. 2000;284(1-2):73-6.
31. Bellantoni G, Guerrini F, Del Maestro M, Galzio R, Luzzi S. Simple schwannomatosis or an incomplete Coffin-Siris? Report of a particular case. eNeurologicalSci. 2019;14:31-3.
32. Fontanella M, Rainero I, Gallone S, Rubino E, Fornaro R, Fenoglio P, et al. Interleukin 1beta–511 C/T polymorphism and risk of aneurysmal subarachnoidal haemorrhage. J Neurosurgery. 2004;100(1-2):59-64.
33. Savasta S, Vrota F, Foialedi T, Campama AM, Persielle E, Marseglia GL, et al. West-Nile virus encephalitis in an immunocompetent pediatric patient: successful recovery. Ital J Pediatr. 2018;44(1):140.
34. Luzzi S, Giotta Lucifero A, Brambilla I, Semeria Manetelli S, Mosconi M, Foialedi T, et al. Targeting the medulloblastoma: a molecular-based approach. Acta Biomed. 2020;91(7-s):79-100.
35. Hendryk S, Jarzab B, Josko J. Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuro Endocrinol Lett. 2004;25(1-2):141-7.
36. Kwon KY, Jeon BC. Cytokine levels in cerebrospinal fluid and delayed ischemic deficits in patients with aneurysmal subarachnoid hemorrhage. J Korean Med Sci. 2001;16(6):774-80.
37. Slowik A, Borraysa A, Turaj W, Pera J, Dziedzic T, Wloch D, et al. Interleukin 1beta–511 C/T polymorphism and aneurysmal SAH. Neuro Endocrinol Lett. 2004;25(1-2):141-7.
38. Sathyan S, Kovsh LV, Srinivas L, Easwer HV, Premkumar N, Sair N, et al. Pathogenesis of intracranial aneurysm is mediated by proinflammatory cytokine TNFA and IFNG and through stochastic regulation of IL10 and TGFb1 by comorbid factors. J Neuroinflammation. 2015;12:135.
39. Xu L, Hu L, Hu C, Liu J, Li B, Liao X, et al. Associations between Inflammatory Cytokine Gene Polymorphisms and Susceptibilities to Intracranial Aneurysm in Chinese Population. Biomed Res Int. 2021;2021:8865601.
40. Garrahy JR, Testai FD. Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: Beyond Vasospasm and Towards a Multifactorial Pathophysiology. Curr Atheroscler Rep. 2017;19(12):50.
lead to systemic upregulation of IL-23/IL-17 inflammatory axis. Cytokine. 2017;97:96–103.
51. Chaudhry SR, Hafez A, Rezai Jahromi B, Kinfe TM, Lamprecht A, Niemelä M, et al. Role of Damage Associated Molecular Pattern Molecules (DAMPs) in Aneurysmal Subarachnoid Hemorrhage (aSAH). Int J Mol Sci. 2018;19(7).
52. Muhammad S, Chaudhry SR, Kahler UD, Lehecka M, Korja M, Niemelä M, et al. Targeting High Mobility Group Box 1 in Subarachnoid Hemorrhage: A Systematic Review. Int J Mol Sci. 2020;21(8).
53. Cahill J, Calvert JW, Solaroglu I, Zhang JH. Vasospasm and p53-induced apoptosis in an experimental model of subarachnoid hemorrhage. Stroke. 2006;37(7):1868–74.
54. Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol. 2007;3(5):256–63.
55. Cahill J, Zhang JH. Subarachnoid hemorrhage: is it time for a new direction? Stroke. 2009;40(3 Suppl):S86–7.
56. Luzzi S, Crovace AM, Del Maestro M, Giotta Lucifero A, Elbahaa SK, Cinque B, et al. The cell-based approach in neurosurgery: ongoing trends and future perspectives. Helicon. 2019;5(11):e02818.
57. Weiland J, Beez A, Westermaier T, Kunze E, Sirén AL, Lilla N. Neuroprotective Strategies in Aneurysmal Subarachnoid Hemorrhage (aSAH). Int J Mol Sci. 2021;22(11).
58. Chaudhry SR, Lehecka M, Niemelä M, Muhammad S. Sterile Inflammation, Potential Target in Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2019;123:159–60.
59. Schneider UC, Xu R, Vajkoczy P. Inflammatory Events Following Subarachnoid Hemorrhage (SAH). Curr Neuropsychopharmacol. 2018;16(9):1385–95.
60. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–20.
61. Hasan DM, Mahaney KB, Brown RD, Jr., Meissner I, Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103–10.
62. Gross BA, Rosalind Lai PM, Frerichs KU, Du R. Aspirin and Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2014;82(6):1127–30.
63. Wiebers DO, Whisnant JP, Huston J, 3rd, Meissner I, Brown RD, Jr., Piepgras DG, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362(9378):103–10.
64. Gross BA, Rosalind Lai PM, Frerichs KU, Du R. Aspirin and Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2014;82(6):1127–30.
65. Yiqin Y, Melin X, Jie X, Keping Z. Aspirin inhibits MMP-2 and MMP-9 expression and activity through PPARalpha/gamma and TIMP-1-mediated mechanisms in cultured mouse celiac macrophages. Inflammation. 2009;32(4):233–41.
66. Sánchez de Miguel L, de Frutos T, González-Fernández F, del Pozo V, Lahoz C, Jiménez A, et al. Aspirin inhibits inducible nitric oxide synthase expression and tumour necrosis factor-alpha release by cultured smooth muscle cells. Eur J Clin Invest. 1999;29(2):93–9.
67. Li S, Wang D, Tian Y, Wei H, Zhou Z, Liu L, et al. Aspirin Inhibits Degenerative Changes of Aneurysmal Wall in a Rat Model. Neurochem Res. 2015;40(7):1537–45.
68. Suzuki T, Kamiyo Y, Makino H, Hokamura K, Kimura T, Yamasaki T, et al. Prevention Effect of Antiplatelets on Aneurysm Rupture in a Mouse Intracranial Aneurysm Model. Cerebrovasc Dis. 2018;45(3–4):180–6.
69. Shen J, Huang KY, Zhu Y, Pan JW, Jiang H, Weng YX, et al. Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Neurosurg. 2017;127(2):291–301.
70. Lin J, Liu H, Jiang J, Jia C, Zhang B, Gao X. Clinical evidence of efficacy of simvastatin for aneurysmal subarachnoid hemorrhage. J Int Med Res. 2017;45(6):2128–38.
71. Marbacher S, Schläppi JA, Fung C, Hüser J, Beck J, Raabe A. Do statins reduce the risk of aneurysm development? A case-control study. J Neurosurg. 2012;116(3):638–42.
72. Terceño M, Remollo S, Silva Y, Bashir S, Werner M, Vera-Monge VA, et al. Effect of combined acetylsalicylic acid and statins treatment on intracranial aneurysm rupture. PLoS One. 2021;16(2):e0247153.
73. Bruder M, Won SY, Wagner M, Brawanski N, Dinc N, Kasbefiolas S, et al. Continuous Acetylsalicylic Acid Treatment Does Not Influence Bleeding Pattern or Outcome of Aneurysmal Subarachnoid Hemorrhage: A Matched-Pair Analysis. World Neurosurg. 2018;113:e122–e8.
74. Bekelis K, Smith J, Zhou W, MacKenzie TA, Roberts DW, Skinner J, et al. Statins and subarachnoid hemorrhage in Medicare patients with unruptured cerebral aneurysms. Int J Stroke. 2015;10 Suppl A100(Suppl A100):38–45.
75. Li P, Gan Y, Sun BL, Zhang F, Lu B, Gao Y, et al. Adoptive regulatory T-cell therapy protects against cerebral ischemia. Ann Neurol. 2013;74(3):458–71.
76. Lei TY, Ye YZ, Zhu XQ, Smerin D, Gu LJ, Xiong XX, et al. The immune response of T cells and therapeutic targets related to regulating the levels of T helper cells after ischaemic stroke. J Neuroinflammation. 2021;18(1):25.
77. Mao L, Li P, Zhu W, Cai W, Liu Z, Wang Y, et al. Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke. Brain. 2017;140(7):1914–31.
78. Zhang HF, Liang GB, Zhao MG, Zhao GF, Luo YH. Regulatory T cells demonstrate significantly increased functions following stimulation with IL-2 in a Tim-3-dependent manner in intracranial aneurysms. Int Immunopharmacol. 2018;65:342–7.
79. Luzzi S, Giotta Lucifero A, Brambilla I, Magistrali M, Mosconi M, Savasta S, et al. Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges. Acta Biomed. 2020;91(7–s):18–31.
80. Han M, Cao Y, Guo X, Chu X, Li T, Xue H, et al. Mes-
enchymal stem cell-derived extracellular vesicles promote microglial M2 polarization after subarachnoid hemorrhage in rats and involve the AMPK/NF-κB signaling pathway. Biomed Pharmacother. 2021;133:111048.

81. Muhammad S, Chaudhry SR, Dobreva G, Lawton MT, Niemelä M, Hänggi D. Vascular Macrophages as Therapeutic Targets to Treat Intracranial Aneurysms. Front Immunol. 2021;12:630381.

82. Zhou K, Zhong Q, Wang YC, Xiong XY, Meng ZY, Zhao T, et al. Regulatory T cells ameliorate intracerebral hemorrhage-induced inflammatory injury by modulating microglia/macrophage polarization through the IL-10/GSK3β/PTEN axis. J Cereb Blood Flow Metab. 2017;37(3):967-79.

83. Luzzi S, Giotta Lucifero A, Brambilla I, Trabatti C, Mosconi M, Savasta S, et al. The impact of stem cells in neuro-oncology: applications, evidence, limitations and challenges. Acta Biomed. 2020;91(7-s):51-60.

84. Liu W, Li R, Yin J, Guo S, Chen Y, Fan H, et al. Mesenchymal stem cells alleviate the early brain injury of subarachnoid hemorrhage partly by suppression of Notch1-dependent neuroinflammation: involvement of Botch. J Neuroinflammation. 2019;16(1):8.

85. Turnbull MT, Zubair AC, Meschia JF, Freeman WD. Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research. NPJ Regen Med. 2019;4:10.

86. Liu J, Kuwabara A, Kamio Y, Hu S, Park J, Hashimoto T, et al. Human Mesenchymal Stem Cell-Derived Microvesicles Prevent the Rupture of Intracranial Aneurysm in Part by Suppression of Mast Cell Activation via a PGE2-Dependent Mechanism. Stem Cells. 2016;34(12):2943-55.

87. Luzzi S, Crovace AM, Lacitignola L, Valentini V, Francioso E, Rossi G, et al. Engraftment, neuroglial transdifferentiation and behavioral recovery after complete spinal cord transection in rats. Surg Neurol Int. 2018;9:19.

88. Raysi Dehcordi S, Ricci A, Di Vitantonio H, De Paulis D, Luzzi S, Palumbo P, et al. Stemness Marker Detection in the Periphery of Glioblastoma and Ability of Glioblastoma to Generate Glioma Stem Cells: Clinical Correlations. World Neurosurg. 2017;105:895-905.

89. Muhammad S, Haasbach E, Kotchourko M, Strigli A, Krenz A, Ridder DA, et al. Influenza virus infection aggravates stroke outcome. Stroke. 2011;42(3):783-91.

90. Muhammad S, Hänggi D. Inflammation and Anti-Inflammatory Targets after Aneurysmal Subarachnoid Hemorrhage. Int J Mol Sci. 2021;22(14).